280 related articles for article (PubMed ID: 29198639)
1. Baseline Multiparametric MRI for Selection of Prostate Cancer Patients Suitable for Active Surveillance: Which Features Matter?
Sanguedolce F; Petralia G; Sokhi H; Tagliabue E; Anyamene N; Hellawell G; Padhani AR
Clin Genitourin Cancer; 2018 Apr; 16(2):155-163.e6. PubMed ID: 29198639
[TBL] [Abstract][Full Text] [Related]
2. Does the Prostate Imaging-Reporting and Data System (PI-RADS) version 2 improve accuracy in reporting anterior lesions on multiparametric magnetic resonance imaging (mpMRI)?
Hoffmann R; Logan C; O'Callaghan M; Gormly K; Chan K; Foreman D
Int Urol Nephrol; 2018 Jan; 50(1):13-19. PubMed ID: 29188489
[TBL] [Abstract][Full Text] [Related]
3. Application of Prostate Imaging Reporting and Data System Version 2 (PI-RADS v2): Interobserver Agreement and Positive Predictive Value for Localization of Intermediate- and High-Grade Prostate Cancers on Multiparametric Magnetic Resonance Imaging.
Chen F; Cen S; Palmer S
Acad Radiol; 2017 Sep; 24(9):1101-1106. PubMed ID: 28546032
[TBL] [Abstract][Full Text] [Related]
4. Multiparametric Magnetic Resonance Imaging Second Opinion May Reduce the Number of Unnecessary Prostate Biopsies: Time to Improve Radiologists' Training Program?
Luzzago S; Petralia G; Musi G; Catellani M; Alessi S; Di Trapani E; Mistretta FA; Serino A; Conti A; Pricolo P; Nazzani S; Mirone V; Matei DV; Montanari E; de Cobelli O
Clin Genitourin Cancer; 2019 Apr; 17(2):88-96. PubMed ID: 30527286
[TBL] [Abstract][Full Text] [Related]
5. Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol.
Luzzago S; Musi G; Catellani M; Russo A; Di Trapani E; Mistretta FA; Bianchi R; Cozzi G; Conti A; Pricolo P; Ferro M; Matei DV; Mirone V; Petralia G; de Cobelli O
Urol Int; 2018; 101(1):56-64. PubMed ID: 29734177
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1.
Tamada T; Kido A; Yamamoto A; Takeuchi M; Miyaji Y; Moriya T; Sone T
J Magn Reson Imaging; 2021 Jan; 53(1):283-291. PubMed ID: 32614123
[TBL] [Abstract][Full Text] [Related]
7. Integration and Diagnostic Accuracy of 3T Nonendorectal coil Prostate Magnetic Resonance Imaging in the Context of Active Surveillance.
Curci NE; Lane BR; Shankar PR; Noyes SL; Moriarity AK; Kubat A; Brede C; Montgomery JS; Auffenberg GB; Miller DC; Montie JE; George AK; Davenport MS
Urology; 2018 Jun; 116():137-143. PubMed ID: 29653121
[TBL] [Abstract][Full Text] [Related]
8. Characterizing indeterminate (Likert-score 3/5) peripheral zone prostate lesions with PSA density, PI-RADS scoring and qualitative descriptors on multiparametric MRI.
Brizmohun Appayya M; Sidhu HS; Dikaios N; Johnston EW; Simmons LA; Freeman A; Kirkham AP; Ahmed HU; Punwani S
Br J Radiol; 2018 Feb; 91(1083):20170645. PubMed ID: 29189042
[TBL] [Abstract][Full Text] [Related]
9. Assessment of PI-RADS v2 for the Detection of Prostate Cancer.
Kasel-Seibert M; Lehmann T; Aschenbach R; Guettler FV; Abubrig M; Grimm MO; Teichgraeber U; Franiel T
Eur J Radiol; 2016 Apr; 85(4):726-31. PubMed ID: 26971415
[TBL] [Abstract][Full Text] [Related]
10. Multiparametric Magnetic Resonance Imaging for the Detection of Clinically Significant Prostate Cancer: What Urologists Need to Know. Part 2: Interpretation.
Israël B; Leest MV; Sedelaar M; Padhani AR; Zámecnik P; Barentsz JO
Eur Urol; 2020 Apr; 77(4):469-480. PubMed ID: 31767492
[TBL] [Abstract][Full Text] [Related]
11. Interobserver Agreement and Accuracy in Interpreting mpMRI of the Prostate: a Systematic Review.
Annamalai A; Fustok JN; Beltran-Perez J; Rashad AT; Krane LS; Triche BL
Curr Urol Rep; 2022 Jan; 23(1):1-10. PubMed ID: 35226257
[TBL] [Abstract][Full Text] [Related]
12. A Prospective Accuracy Study of Prostate Imaging Reporting and Data System Version 2 on Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer With Whole-mount Pathology.
Giannarini G; Girometti R; Crestani A; Rossanese M; Calandriello M; Cereser L; Bednarova S; Battistella C; Sioletic S; Zuiani C; Valotto C; Ficarra V
Urology; 2019 Jan; 123():191-197. PubMed ID: 30273613
[TBL] [Abstract][Full Text] [Related]
13. Likert vs PI-RADS v2: a comparison of two radiological scoring systems for detection of clinically significant prostate cancer.
Khoo CC; Eldred-Evans D; Peters M; Bertoncelli Tanaka M; Noureldin M; Miah S; Shah T; Connor MJ; Reddy D; Clark M; Lakhani A; Rockall A; Hosking-Jervis F; Cullen E; Arya M; Hrouda D; Qazi H; Winkler M; Tam H; Ahmed HU
BJU Int; 2020 Jan; 125(1):49-55. PubMed ID: 31599113
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Multiparametric MRI Scoring Systems and the Impact on Cancer Detection in Patients Undergoing MR US Fusion Guided Prostate Biopsies.
Rastinehad AR; Waingankar N; Turkbey B; Yaskiv O; Sonstegard AM; Fakhoury M; Olsson CA; Siegel DN; Choyke PL; Ben-Levi E; Villani R
PLoS One; 2015; 10(11):e0143404. PubMed ID: 26605548
[TBL] [Abstract][Full Text] [Related]
15. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
[TBL] [Abstract][Full Text] [Related]
16. Direct comparison of PI-RADS version 2 and version 1 regarding interreader agreement and diagnostic accuracy for the detection of clinically significant prostate cancer.
Becker AS; Cornelius A; Reiner CS; Stocker D; Ulbrich EJ; Barth BK; Mortezavi A; Eberli D; Donati OF
Eur J Radiol; 2017 Sep; 94():58-63. PubMed ID: 28941761
[TBL] [Abstract][Full Text] [Related]
17. The efficiency of multiparametric magnetic resonance imaging (mpMRI) using PI-RADS Version 2 in the diagnosis of clinically significant prostate cancer.
Zhao C; Gao G; Fang D; Li F; Yang X; Wang H; He Q; Wang X
Clin Imaging; 2016; 40(5):885-8. PubMed ID: 27179959
[TBL] [Abstract][Full Text] [Related]
18. Interreader agreement of PI-RADS v. 2 in assessing prostate cancer with multiparametric MRI: A study using whole-mount histology as the standard of reference.
Girometti R; Giannarini G; Greco F; Isola M; Cereser L; Como G; Sioletic S; Pizzolitto S; Crestani A; Ficarra V; Zuiani C
J Magn Reson Imaging; 2019 Feb; 49(2):546-555. PubMed ID: 30187600
[TBL] [Abstract][Full Text] [Related]
19. 1.5-T multiparametric MRI using PI-RADS: a region by region analysis to localize the index-tumor of prostate cancer in patients undergoing prostatectomy.
Reisæter LA; Fütterer JJ; Halvorsen OJ; Nygård Y; Biermann M; Andersen E; Gravdal K; Haukaas S; Monssen JA; Huisman HJ; Akslen LA; Beisland C; Rørvik J
Acta Radiol; 2015 Apr; 56(4):500-11. PubMed ID: 24819231
[TBL] [Abstract][Full Text] [Related]
20. Clinically insignificant prostate cancer suitable for active surveillance according to Prostate Cancer Research International: Active surveillance criteria: Utility of PI-RADS v2.
Yim JH; Kim CK; Kim JH
J Magn Reson Imaging; 2018 Apr; 47(4):1072-1079. PubMed ID: 28901655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
